Drug innovation is becoming an important force in promoting the improvement of diabetes treatment level .The company announced that its investigational oral GLP-1 drug orforglipron achieved the primary endpoint and all key secondary endpoints in two Phase 3 clinical trials, ACHIEVE-2 and ACHIEVE-5, reaffirming its potential as a basic treatment for type 2 diabetes.

The ACHIEVE-2 study directly addresses the vast patient population whose glycemic control remains poor despite classic first-line treatments. It conducted a head-to-head evaluation of the efficacy and safety of oral orforglipron compared with dapagliflozin in adults with type 2 diabetes whose glycemic control is inadequate despite metformin treatment. The new drug demonstrated significant superiority over dapagliflozin in lowering A1C, a key marker of glycated hemoglobin, achieving a 1.7% reduction in A1C compared to a 0.8% reduction with dapagliflozin. This is the second head-to-head trial in this series by Eli Lilly and Company, following the previous head-to-head trial, ACHIEVE-3, which demonstrated orforglipron's superior efficacy to oral semaglutide.

The ACHIEVE-5 study focuses on a more complex diabetic population, including patients with type 2 diabetes whose blood sugar remains poorly controlled despite treatment with insulin glargine (alone or in combination with metformin and/or an SGLT-2 inhibitor). In this study, the new drug, when used in combination with insulin glargine, achieved an additional 2.1% reduction in A1C, significantly outperforming placebo, providing clinicians with a powerful potential treatment option and bringing new hope to these patients..

"Orforglipron has demonstrated superiority in two type 2 diabetes clinical studies compared to active comparators," said Jeff Emmick, senior vice president of Cardiometabolic Health Product Development at Lilly . "In ACHIEVE-2, orforglipron outperformed the widely used SGLT-2 inhibitor dapagliflozin, and in ACHIEVE-3, orforglipron surpassed oral semaglutide. Results from ACHIEVE-5 build on this momentum, demonstrating that orforglipron significantly reduced A1C and body weight when used in combination with titrated basal insulin. These data further support orforglipron's potential to become a new standard of care for type 2 diabetes."

One of the core challenges facing diabetes management has long been patient compliance due to the inconvenience of treatment. Eli Lilly's newly developed oral small-molecule GLP-1 drug requires no strict dietary restrictions and only needs to be taken once daily. This advancement lowers the barrier to adherence and makes long-term, standardized treatment more feasible. This represents not only a technological advancement but also a profound demonstration of the company's patient-centric R&D philosophy, a significant advancement in the transition from disease treatment to comprehensive health management.

In both studies, the overall safety and tolerability profile and discontinuation rates of orforglipron were consistent with previous studies. Detailed results from these trials will be presented at future medical conferences and published in peer-reviewed journals. Results from ACHIEVE-4, the final global registration study in the ACHIEVE project, are expected to be announced in the first quarter of 2026. Eli Lilly and Company plans to submit an application to global regulatory authorities in 2026 for orforglipron for the treatment of type 2 diabetes. If approved, the drug is expected to become an important supplement to the treatment of type 2 diabetes, providing more precise, personalized and sustainable treatment options for patients with poor blood sugar control or who require intensive treatment. In addition, the application for orforglipron's obesity treatment indication is expected to be completed by the end of this year.

As China actively promotes the construction of a patient-centered innovation ecosystem and medical regulatory system, similar global innovation achievements are expected to benefit Chinese patients more quickly in the future, helping to achieve the strategic goal of "Healthy China 2030".

https://finance.eastmoney.com/a/202510163535901163.html